Pharmacokinetics of antibiotics in burn patients

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 3, 1999, Pages 319-327

  Weinbren, M J ^a,b  

^a Hospital of Coventry and Warwickshire   (United Kingdom)

^b QUEEN MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; TEICOPLANIN; TICARCILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BURN; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; MAJOR CLINICAL STUDY; REVIEW; SEPTICEMIA;

EID: 0032834329     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.3.319     Document Type: Review

References (33)

1. Jaehde, U. & Sorgel, F. (1995). Clinical pharmacokinetics in patients with burns. Clinical Pharmacokine 29, 15-28.
2. Boucher, B. A., Kuhl, D. A. & Hickerson, W. L. (1992). Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clinical Infectious Diseases 14, 458-63.
3. Timmons, M. J. (1983). Are systemic antibiotics necessary for burns? Annals of the Royal College of Surgeons of England 65, 80-2.
4. Beard, C. H., Ribeiro, C. D. & Jones, D. M. (1975). The bacteraemia associated with burns surgery. British Journal of Surgery 62, 638-41.
5. Zaske, D. E., Sawchuk, R. J., Gerding, D. N. & Strate, R. G. (1976). Increased dosage requirements of gentamicin in burn patients. Journal of Trauma 6, 824-8.
6. Hollingsed, T. C., Harper, D. J., Jennings, P., Morris, S. E. & Saffle, J. R. (1993). Aminoglycoside dosing in burn patients using first-dose pharmacokinetics. Journal of Trauma 35, 394-8.
7. Moore, R. D., Smith, C. R. & Lietman, P. S. (1984). The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. Journal of Infectious Diseases 149, 443-8.
8. Noone, P., Parsons, T. M. C., Pattison, J. R., Slack, R. C., Garfield-Davies, D. & Hughes, K. (1974). Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. British Medical Journal 1, 477-81.
9. Zaske, D. E. & Cipolle, R. J. (1981). Rapid individualization of gentamicin dosage regimens in 66 burn patients. Burns 7, 215-20.
10. Zaske, D. E., Chin, T., Kohls, P. R., Solem, L. D. & Strate, R. G. (1991). Initial dosage regimens of gentamicin in patients with burns. Journal of Burn Care and Rehabilitation 12, 47-50.
11. Hoey, L. L., Tschida, S. J., Rotschafer, J. C., Quay, D. R. P. & Vance-Bryan, K. (1997). Wide variation in single, daily-dose amino-glycoside pharmacokinetics in patients with burn injuries. Journal of Bum Care and Rehabilitation 18, 116-24.
12. Rybak, M. J., Albrecht, L. M., Berman, J. R., Warbasse, L. H. & Svensson, C. K. (1990). Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrobial Agents and Chemotherapy 34, 792-5.
13. Garrelts, J. C. & Peterie, J. D. (1988). Altered vancomycin dose vs. serum concentration relationship in burns patients. Clinical Pharmacology and Therapeutics 44, 9-13.
14. Brater, D. C., Bawdon, R. E., Anderson, S. A., Purdue, G. F. & Hunt, J. L. (1986). Vancomycin elimination in patients with burn injury. Clinical Pharmacology and Therapeutics 39, 631-4.
15. Moellering, R. C. (1994). Monitoring serum vancomycin levels: climbing the mountain because it is there? Clinical Infectious Diseases 18, 544-6.
16. James, J. K., Palmer, S. M., Levine, D. P. & Rybak, M. J. (1996). Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrobial Agents and Chemotherapy 40, 696-700.
17. Conil, J. M., Favarel, H., Laguerre, J., Brouchet, A., Chabanon, G., Cazal, L. et al. (1994). Vancomycin: continuous administration in severely burned patients. Presse Medicale 23, 1554-8.
18. Lucet, J. C., Bedos, J. P. & Décré, D. (1991). Emergence de la résistance à la rifampicine au course de traitment par vancomycine-rifampicine des infections graves à stapylocouque doreé. In Vancocine en 1991 pour une Utilisation Optimisée. Symposium organisé par Lilly France sur la vancomycine Lilly, p. 7.
19. Regnier, B. (1988). Antibiothérapie des infections à staphylocoques. In L'infection en Réanimation, Vol. 10. (Regnier, B. & Brun-Buisson, C., Eds.), pp. 217-29. Masson Collection d'Anesthésiologie et de Réanimation.
20. Martin, C., Perrin, G. & Denis, J. P. (1992). Choix d'une antibiothérapie pour le traitment d'une infection à staphylocoque. In Antibiothérapie en Réanimation et Chirurgie, (Martin, C. & Gouin, F., Eds), pp. 367-7. Arnette.
21. Wysocki, M., Woolff, M. & Pean, T. (1991). Traitement des infections graves à staphylocoque par perfusion continue de vancomycine: tolérance rénale. RICAI, Paris, Abstract Communication, p. 208.
22. Steer, J. A., Papini, R. P. G., Wilson, A. P. R., Dhillon, S., Hickens, M. F., McGrouther, D. A. et al. (1996). Pharmacokinetics of a single dose of teicoplanin in burn patients. Journal of Antimicrobial Chemotherapy 37, 545-53.
23. Potel, G., Moutet, J., Bernareggi, A., Le Normand, Y., Meigner, M. & Baron, D. (1990). Pharmacokinetics of teicoplanin in burn patients. Scandinavian Journal of Infectious Diseases 22, Suppl. 72, 29-34.
24. Lesne Hulin, A., Bourget, P., Le Bever, H., Ainaud, P. & Carsin, H. (1997). Monitoring of teicoplanin in a major burn patient. Annales Francaises d'Anesthesie et de Reanimation 16, 374-7.
25. Wilson, A. P. R. & Grüneberg, R. N. (1997). Dosage issues and the need for serum assay. In Teicoplanin: the First Decade, (Wilson, A. P. R. & Gruneberg, R. N., Eds), pp. 103-34. The Medicine Group, Oxford, UK.
26. Adam, D., Zellner, P. R., Koeppe, P. & Wesch, R. (1989). Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. Journal of Antimicrobial Chemotherapy 24, Suppl. B, 121-30.
27. Walstad, R. A., Aanderud, L. & Thurmann-Nielsen, E. (1988). Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. European Journal of Clinical Pharmacology 35, 543-9.
28. Rio, Y., Leroy, F., Humbert, G., Didion, J. & Jurin, F. (1994). Comparative ceftazidime serum concentrations during continuous infusion in healthy subjects and severe burn patients. In Programme and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract A13, p. 16. American Society for Microbiology, Washington, DC.
29. Boucher, B. A., Hickerson, W. L., Kuhl, D. A., Bombassaro, A. M. & Jaresko, G. S. (1990). Imipenem Pharmacokinetics in patients with burns. Clinical Pharmacology and Therapeutics 48, 131-7.
30. Yoshida, T., Homma, K., Fujioka, H. & Ohura, T. (1993). Fundamental and clinical studies on meropenem in burn infections. Journal of Chemotherapy 5, Suppl. 1, 142-3.
31. Metz, R., Weber, G., Sorgel, F. & Labisch, C. (1989). Pharmacokinetics of ciprofloxacin in patients with burn injuries. Reviews of Infectious Diseases 11, Suppl. 5, S1012-3.
32. Garrelts, J. C., Jost, G., Kowalsky, S. F., Krol, G. J. & Lettieri, J. T. (1996). Ciprofloxacin pharmacokinetics in burn patients. Antimicrobial Agents and Chemotherapy 40, 1153-6.
33. Forrest, A., Ballow, C. H., Nix, D. E., Birmingham, M. C. & Schentag, J. J. (1993). Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy 37, 1065-72.